CV Sciences, Inc. (CVSI)
OTCMKTS
· Delayed Price · Currency is USD
0.0400
+0.0006 (1.52%)
Jun 27, 2025, 3:32 PM EDT
CV Sciences Revenue
CV Sciences had revenue of $3.61M in the quarter ending March 31, 2025, a decrease of -9.90%. This brings the company's revenue in the last twelve months to $15.31M, down -3.46% year-over-year. In the year 2024, CV Sciences had annual revenue of $15.71M, down -1.87%.
Revenue (ttm)
15.31M
Revenue Growth
-3.46%
P/S Ratio
0.48
Revenue / Employee
318.94K
Employees
49
Market Cap
7.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15.71M | -299.00K | -1.87% |
Dec 31, 2023 | 16.00M | -201.00K | -1.24% |
Dec 31, 2022 | 16.21M | -3.84M | -19.17% |
Dec 31, 2021 | 20.05M | -4.38M | -17.93% |
Dec 31, 2020 | 24.43M | -29.27M | -54.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
CV Sciences News
- 4 days ago - Bullish Sentiment Across The Cannabis Space - Check Full Movers For June 24, 2025 - Benzinga
- 5 days ago - CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3 - Accesswire
- 15 days ago - Cannabis Stock Gainers And Losers From June 13, 2025 - Benzinga
- 4 weeks ago - Cannabis Stock Gainers And Losers From May 29, 2025 - Benzinga
- 5 weeks ago - Cannabis Stock Movers For May 20, 2025 - Benzinga
- 6 weeks ago - Marijuana Stock Movers For May 15, 2025 - Benzinga
- 6 weeks ago - CV Sciences Non-GAAP EPS of $0.00, revenue of $3.6M - Seeking Alpha
- 6 weeks ago - CV Sciences targets cost efficiency gains and product diversification with in-source manufacturing and non-cannabinoid launches - Seeking Alpha